STOCK TITAN

Intellia Therapeutics, Inc - NTLA STOCK NEWS

Welcome to our dedicated page for Intellia Therapeutics news (Ticker: NTLA), a resource for investors and traders seeking the latest updates and insights on Intellia Therapeutics stock.

Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a pioneering clinical-stage gene editing company dedicated to revolutionizing medicine through the use of CRISPR-based therapies. Founded in 2014 by Caribou Biosciences and Atlas Venture, along with leading scientists in the field, Intellia harnesses the potential of CRISPR/Cas9 technology to develop curative treatments for a variety of genetically defined diseases.

The company's core mission is to leverage CRISPR/Cas9—an innovative technology adapted from a natural cellular process that allows for precise and flexible gene editing. This technology enables the correction of specific DNA sequences within any organism, opening new frontiers in biomedical research and clinical interventions.

Intellia's portfolio includes both in vivo and ex vivo gene editing programs. The in vivo programs aim to edit disease-causing genes directly within the human body, targeting conditions such as ATTR amyloidosis, hereditary angioedema (HAE), and alpha-1 antitrypsin deficiency. Notable achievements include the interim results from their NTLA-2002 program for HAE, which showed a 95% reduction in monthly attack rates, with most patients remaining attack-free.

The ex vivo programs focus on engineering human cells outside the body to treat cancer and autoimmune diseases. These programs include collaborations with prominent companies like Regeneron and Novartis, which help advance their therapeutic pipeline.

Intellia's financial condition reflects its robust pipeline and strategic partnerships. The company recently reported strong enrollment progress in their pivotal Phase 3 MAGNITUDE trial for NTLA-2001 targeted at ATTR amyloidosis with cardiomyopathy. They have also formed a strategic collaboration with ReCode Therapeutics to develop treatments for cystic fibrosis, utilizing ReCode's Selective Organ Targeting (SORT) lipid nanoparticle delivery platform.

Committed to advancing the field of gene editing, Intellia continues to expand its CRISPR-based platform with novel editing and delivery technologies. The company remains at the forefront of a new era in medicine, as evidenced by its ongoing clinical trials and promising preliminary data.

For more detailed information and the latest updates, investors and stakeholders are encouraged to visit www.intelliatx.com and follow Intellia on Twitter @intelliatx.

Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) reported its Q4 2021 results, showcasing significant growth and strategic advancements in its CRISPR-based pipeline. The company plans to present additional interim data from its Phase 1 study on NTLA-2001 for ATTR amyloidosis on February 28, 2022. Notably, Intellia announced two new candidates, NTLA-6001 for hematologic cancers and NTLA-2003 for liver-related AATD. With $1.086 billion in cash as of year-end 2021, up from $597.4 million in 2020, Intellia is well-positioned for future developments. Net loss rose to $81.2 million, emphasizing the costs of advancing multiple clinical programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.26%
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) has announced a lease agreement for a new 140,000-square-foot GMP manufacturing facility in Waltham, Massachusetts, expected to be operational in 2024. This facility will support the production of components for its CRISPR-based investigational therapies, enhancing manufacturing capacity and capability as the company advances its pipeline. Intellia's Chief Technical Officer emphasized the strategic importance of this investment for efficient production, while the Chief Financial Officer noted the benefits of a long-term lease over building a facility.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) has announced two virtual investor events in February 2022. The first is the Fourth Quarter and Full-Year 2021 Financial Results, scheduled for February 24 at 8:00 a.m. ET. U.S. callers can dial 1-833-316-0545 to join. The second event is an update on interim clinical data for NTLA-2001, set for February 28 at 4:30 p.m. ET, featuring presentations from leading experts. NTLA-2001 aims to treat ATTR amyloidosis using CRISPR technology, potentially allowing for a single-dose treatment option.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.7%
Tags
conferences
Rhea-AI Summary

Intellia Therapeutics (NTLA) and ONK Therapeutics have entered a collaboration to develop CRISPR-edited NK cell therapies for cancer treatment. ONK receives non-exclusive rights to Intellia's ex vivo genome editing and delivery technologies for up to five therapies, while Intellia is eligible for $184 million per product in milestone payments and royalties. The agreement allows for co-development of two therapies, with Intellia holding lead commercialization rights in the U.S. This collaboration aims to enhance NK cell efficacy against various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.09%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced its acquisition of Rewrite Therapeutics for $45 million upfront, plus up to $155 million in milestones. This strategic acquisition enhances Intellia's genome editing capabilities, integrating Rewrite's novel DNA writing platform. Rewrite’s technology promises precise gene editing solutions, including targeted corrections and edits in non-dividing cells, facilitating potential advancements in genomic medicine. The merger is expected to expand Intellia’s therapeutic applications, aligning with its mission to develop curative CRISPR-based therapeutics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.9%
Tags
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ:NTLA) announced significant advancements in its clinical development pipeline for 2022. The company is progressing NTLA-2001 for transthyretin amyloidosis, with additional Phase 1 study data expected in Q1 2022. NTLA-2002 is also in development for hereditary angioedema, with interim data anticipated in 2H 2022. The firm is establishing the safety profile of NTLA-5001 for acute myeloid leukemia and plans to nominate new development candidates. Intellia ended 2021 with a robust cash position of $1.1 billion.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
none
Rhea-AI Summary

Intellia Therapeutics, Inc. (NASDAQ:NTLA) will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 2:15 p.m. ET. This leading clinical-stage genome editing company focuses on developing CRISPR-based therapeutics. Interested parties can access a live audio webcast of the presentation on Intellia’s website, with a replay available for two weeks afterward.

Intellia is advancing innovative therapies through in vivo and ex vivo CRISPR programs, demonstrating its leadership in genetic medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
conferences
-
Rhea-AI Summary

Intellia Therapeutics (NTLA) has entered a collaboration with Kyverna Therapeutics to develop KYV-201, an allogeneic CD19 CAR T-cell therapy targeting autoimmune diseases. Under the agreement, Kyverna will lead preclinical and clinical development, while Intellia will gain an equity stake and potential royalties on sales. Intellia retains the option to co-develop KYV-201 in the U.S., sharing development costs and revenue. The partnership aims to leverage Intellia's CRISPR technology, allowing for improved safety and efficacy in autoimmune treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.97%
Tags
none
-
Rhea-AI Summary

Intellia Therapeutics (NASDAQ: NTLA) has appointed Derek Hicks as the new Executive Vice President, Chief Business Officer. With over 25 years of experience, Hicks previously led business development at Spark Therapeutics and held significant roles at Pfizer. Intellia's President John Leonard expressed confidence that Hicks will enhance their growth and collaboration strategies in genome editing, emphasizing the company's commitment to developing innovative therapeutics using CRISPR/Cas9 technology. Hicks is eager to join Intellia at this pivotal moment in its evolution.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.36%
Tags
management
Rhea-AI Summary

Intellia Therapeutics (NTLA) reports significant progress with NTLA-2002, the first single-dose CRISPR gene-editing therapy for hereditary angioedema (HAE). The first patient has been successfully dosed in a Phase 1/2 study designed to evaluate safety, tolerability, and pharmacodynamics. The therapy aims to inactivate the kallikrein B1 (KLKB1) gene, reducing plasma kallikrein activity to prevent HAE attacks. This innovative treatment has the potential to drastically lower treatment burdens for patients with HAE.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.21%
Tags

FAQ

What is the current stock price of Intellia Therapeutics (NTLA)?

The current stock price of Intellia Therapeutics (NTLA) is $12.18 as of December 20, 2024.

What is the market cap of Intellia Therapeutics (NTLA)?

The market cap of Intellia Therapeutics (NTLA) is approximately 1.3B.

What is the mission of Intellia Therapeutics?

Intellia Therapeutics aims to develop curative medicines using CRISPR/Cas9 gene editing technology.

What diseases is Intellia targeting with their CRISPR-based therapies?

Intellia targets genetically defined diseases such as ATTR amyloidosis, hereditary angioedema (HAE), sickle cell disease, and cystic fibrosis.

What are Intellia's key advancements in hereditary angioedema (HAE) treatment?

Intellia's NTLA-2002 program for HAE has shown a 95% reduction in monthly attack rates, with most patients remaining attack-free.

When was Intellia Therapeutics founded?

Intellia Therapeutics was founded in 2014.

Who are Intellia's key collaborators?

Intellia has collaborations with Regeneron, Novartis, and ReCode Therapeutics.

What is CRISPR/Cas9?

CRISPR/Cas9 is a gene editing technology that allows for precise modification of DNA sequences, adapted from a natural cellular process.

How does Intellia's in vivo program work?

Intellia's in vivo programs use CRISPR to edit disease-causing genes directly inside the human body.

What are the recent financial highlights of Intellia Therapeutics?

Intellia recently reported strong enrollment progress in their Phase 3 MAGNITUDE trial for NTLA-2001.

What is the scope of Intellia's collaboration with ReCode Therapeutics?

The collaboration aims to develop genomic medicines for cystic fibrosis using Intellia's CRISPR-based platform and ReCode's SORT LNP delivery platform.

Where can I find more information about Intellia Therapeutics?

Visit Intellia's website at www.intelliatx.com and follow them on Twitter @intelliatx.

Intellia Therapeutics, Inc

Nasdaq:NTLA

NTLA Rankings

NTLA Stock Data

1.26B
100.15M
1.21%
91.4%
16.07%
Biotechnology
In Vitro & in Vivo Diagnostic Substances
Link
United States of America
CAMBRIDGE